Patients reported early, sustained improvement in a chronic-cough trial
Trevi Therapeutics (TRVI) announced that Phase 2b CORAL trial results for nalbuphine ER in treating chronic cough in IPF patients will be presented at CHEST 2026. The trial showed early, sustained improvement in patient-reported outcomes. Trevi is developing Haduvio (nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and RCC, areas with high unmet medical need.
How this was made
The 30-second read
Why it matters
The acceptance of patient-reported outcomes for an oral presentation can strengthen the clinical story and improve investor confidence, but the release provides no new quantitative results or regulatory action.
Market read
This is a pre-conference clinical communications catalyst that can move sentiment, especially for traders tracking ILD and chronic-cough pipeline updates.
What to watch
Investors will likely focus on whether the PRO improvements align with objective cough-frequency results and on safety/tolerability details that are not provided in this release.
Background
Trevi is developing oral nalbuphine ER (Haduvio) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough, with the Phase 2b CORAL trial evaluating multiple doses versus placebo over 6 weeks.
Ticker impact
Trevi Therapeutics announced Phase 2b CORAL trial patient-reported outcomes were accepted for CHEST 2026, supporting early and sustained cough improvement with nalbuphine ER.
Shares may see incremental upside as investors price improved clinical read-through ahead of further trial disclosures, but magnitude is likely limited until full data are presented and validated.
The article is a clinical-trial communications update (PRO acceptance) with no new efficacy numbers or regulatory milestones disclosed, which typically supports sentiment but not a decisive repricing.
Market effects
Adds incremental momentum to the ILD and chronic-cough therapeutic pipeline narrative for clinical-stage biopharma, but without sector-wide guidance changes.
Primarily US small/mid-cap biotech sentiment tied to upcoming conference data.
Limited, as the catalyst is a US conference presentation and company-specific trial communications.
Counterpoint
PRO acceptance does not guarantee the primary endpoint outcome or magnitude of benefit; without the full dataset, the market may discount the impact.
Key entities
- companyTrevi Therapeutics, Inc.
Clinical-stage biopharmaceutical developing oral nalbuphine ER (Haduvio) for chronic cough in IPF and other indications.
- clinical_trialPhase 2b CORAL trial
Double-blind, randomized, placebo-controlled trial of nalbuphine ER in IPF patients with chronic cough; PROs accepted for CHEST 2026 oral presentation.
- conferenceCHEST 2026 Annual Meeting (American College of Chest Physicians)
Conference where the PRO results are scheduled for an oral presentation on Oct. 20, 2026.
